Why Tonix Pharmaceuticals (TNXP) Stock Is Moving

Tonix Pharmaceuticals Holding Corp TNXP shares are trading higher by 1.18% to $0.14 during Tuesday’s session after the company secured a $34 million DOD research collaboration contract with X-Chem.

What To Know: Tonix Pharmaceuticals announced a research collaboration with X-Chem to accelerate the development of its TNX-4200 oral broad-spectrum antiviral program. The collaboration will leverage X-Chem’s AI and machine learning technologies to optimize the drug's properties, safety and pharmacokinetics.

The company says TNX-4200 focuses on oral CD45 phosphatase inhibitors with broad-spectrum antiviral potential, supported by a $34 million contract from the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA).

Tonix says the DTRA funding will help advance the TNX-4200 program through key development stages, including an IND submission and a first-in-human Phase 1 trial. Tonix is meanwhile utilizing its R&D facilities in Maryland for the project.

Read Also: As Florida Prepares For One Of Deadliest Hurricanes, Here Are Some Potential Stock Winners And Losers From Milton Threat

How To Buy TNXP Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Tonix Pharmaceuticals TNXP's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, TNXP has a 52-week high of $22.14 and a 52-week low of $0.12.